Physician profile
Eric P Roger
NPI 1477561280
$149,514.40
in general payments reported to CMS, 2019-2025
13 companies · $4,476 in 2025
The $4,476 reported for 2025 was more than what 79% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $38K · 2021: $32K · 2022: $28K · 2023: $6,099 · 2024: $5,573 · 2025: $4,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $12K · Consulting Fee: $2,500 · Food and Beverage: $1,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $11,743.07 |
| Consulting Fee | $2,500.00 |
| Food and Beverage | $1,905.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surgalign Spine Technologies, INC. | $123,372.23 | 2019-2022 | |
| Globus Medical, INC. | $17,561.61 | 2019-2025 | Aerial, Senza |
| Xtant Medical INC | $2,792.82 | 2023-2025 | |
| Clariance Sas | $2,500.00 | 2024 | Elegance |
| Abbott Laboratories | $1,047.17 | 2019-2025 | Penta, Proclaim, Eterna |
| Clariance, INC. | $823.43 | 2021-2025 | Elegance, Aggeris-C, Aptofuse |
| Boston Scientific Corporation | $446.63 | 2022-2023 | Wavewriter Alpha Prime 16 |
| Nevro Corp. | $421.77 | 2020-2024 | Senza |
| Saluda Medical Americas, INC. | $239.98 | 2024-2025 | Evoke |
| Medtronic USA, INC. | $117.58 | 2019 | |
| Life Spine, INC. | $84.30 | 2019 | |
| Solventum Corporation | $79.60 | 2025 | Prevena |
| Si-Bone, INC. | $27.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Roger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.